Theravance To Receive Milestone Payment From Viatris For Regulatory Approval Of YUPELRI In China

Theravance Biopharma (TBPH) announced that Viatris Inc. secured regulatory approval from China's National Medical Products Administration for YUPELRI inhalation solution, the first once-daily nebulized long-acting muscarinic antagonist for COPD maintenance in China. This approval triggers a one-time $7.5 million milestone payment to Theravance, expected in Q3 2025, alongside eligibility for up to $37.5 million in additional sales-based milestones and tiered royalties of 14% to 20% on net sales in China, establishing a significant new revenue stream for TBPH from the Chinese market.

Analysis

Theravance Biopharma (TBPH) has secured a significant catalyst through its partner Viatris's regulatory approval for YUPELRI in China. This approval is particularly noteworthy as YUPELRI is the first once-daily nebulized long-acting muscarinic antagonist (LAMA) for COPD maintenance in the substantial Chinese market, granting it a first-mover advantage. The financial implications for TBPH are clearly defined and positive, beginning with a guaranteed $7.5 million milestone payment due in Q3 2025. More importantly, this event unlocks a long-term, high-margin revenue stream through tiered royalties ranging from 14% to 20% on Chinese net sales, supplemented by up to $37.5 million in potential sales-based milestones. This development de-risks a key asset in TBPH's portfolio and establishes a tangible monetization path in a major global healthcare market, directly supporting the strongly positive sentiment associated with the company.

Key Decisions for Investors

• Investors should update valuation models for Theravance Biopharma to incorporate the new, high-margin royalty stream from the Chinese market, which provides a clearer long-term revenue trajectory.
• Monitor Viatris's commercial execution and sales ramp-up of YUPELRI in China, as the realization of the $37.5 million in milestones and the magnitude of royalty payments are entirely dependent on future sales performance.
• Consider this regulatory success a validation of TBPH's partnership strategy, and evaluate the potential of other pipeline assets that rely on similar collaborations for market access and commercialization.